- Sephadex and Cytodex families of products are used in the manufacturing of plasma derived life-saving therapies and vaccines
- The manufacturing site in Uppsala, Sweden has been updated and expanded to accommodate growing demand for those products
June 21, 2022
Cytiva facility - Uppsala
President and CEO Emmanuel Ligner cuts the ribbon while site leader Cecilia Sjöstedt looks on.
Cytiva is opening a new, larger facility on its Uppsala site to expand its manufacturing capacity of the Sephadex and Cytodex product families.
Sephadex products are used primarily to purify plasma-based medicines such as coagulation factors, immunoglobulin, albumin and more. Patients receiving blood transfusions, or those with auto-immune diseases, leukemia, jaundice, or other similar conditions that affect the blood, need plasma-based medicines in their treatments. Cytodex is used for cell culture of adherent cell lines and enables the manufacturing of life-saving vaccines such as Polio or COVID-19 vaccines.
Sofie Stille, General Manager, Resins and Technologies, Cytiva, says: “There are more than 2000 components in plasma and more than 20 therapies that are currently approved using this technology. Research is ongoing but we know that the possibilities are great, and that’s why we have prioritized the expansion of this facility, so that we can enable bringing life-changing therapies to patients faster and more efficiently.”
The increased demand for Sephadex products is driven by the overall blood plasma market growth, and our customers expanding their manufacturing. Cytodex is used in vaccine manufacturing, which has seen a significant growth in demand over the past years.
The expansion project has been ongoing since 2018. The new facility adds approximately 40% capacity above the current level to the overall Sephadex and Cytodex manufacturing.
About Cytiva
Cytiva is a global life sciences leader that works with academic and translational researchers, developers and manufacturers of biotherapeutics, cell and gene therapies, and new technologies such as mRNA, to enable the delivery of transformative medicines. Cytiva is a trusted expert with nearly 10 000 associates in more than 40 countries dedicated to customers’ speed, flexibility, capacity and efficiency in drug discovery, research, and manufacturing.
About Cytiva
Dodi Axelson
[email protected]
Cytiva and the Drop logo are trademarks of Life Sciences IP Holdings Corp. Sephadex and Cytodex are trademarks of Global Life Sciences Solutions USA LLC or an affiliate doing business as Cytiva. ©2022 Cytiva